Drug intelligence / Profile preview

mV002

Development stage: Phase 1
Lead developer: MV BioTherapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Injection

Overview

mV002 is an investigational multi-target mRNA vaccine developed by the Second Affiliated Hospital, School of Medicine, Zhejiang University for the treatment of recurrent or progressive high-grade glioma. The vaccine is designed to encode seven specific glioma-associated mutations: H3.3K27M, H3.1K27M, H3.3G34R, BRAF V600E, PIK3CA H1047R, IDH1 R132H, and EGFRvIII. By introducing these mRNA sequences, mV002 aims to stimulate the patient's immune system to recognize and attack tumor cells expressing these specific oncogenic drivers. It is currently being evaluated in an exploratory Phase I clinical trial to assess its safety, tolerability, and preliminary efficacy in patients whose tumors harbor these mutations.

Other names: Glioma-related multi-target mRNA vaccinesUniversal mRNA Vaccine for Recurrent or Progressive High-grade Glioma

Targets

Glioma-associated mutant neoantigen

Beyond the preview

Go deeper on mV002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mV002.

Explore the full profile